Dual nanobody CAR-T cells for DSA-positive transplant patients
Part of Blood & lymphatic clinical trials.
This trial tests a new type of cell therapy using your own immune cells to target two proteins (CD19 and BCMA) to help reduce DSA antibodies before a stem cell transplant. It is for patients who have high levels of DSA and are planning to receive a transplant from a half-matched family donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal guardian must agree to join the study and sign the consent form.
- You must be 3 years old or older.
- You must be planning to get a stem cell transplant from a half-matched family donor.
- Your DSA level must be 5000 MFI or higher.
- You must not have a fully matched sibling or unrelated donor, and no DSA-negative relative donor.
- Your liver, kidney, heart, and lung function must meet the study's minimum requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It's for people whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments.
This early-stage trial tests a new type of cell therapy (CAR-T) that targets two proteins on plasma cell cancer cells. The treatment uses your own immune cells modified in the lab to recognize and attack cancer cells that have come back or stopped responding to standard drugs.
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
Hear when a new Transplantation Candidates With Hematological Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.